Journal article
Phase II Study of Weekly Intravenous Oxaliplatin Combined With Oral Daily Capecitabine and Radiotherapy With Biologic Correlates in Neoadjuvant Treatment of Rectal Adenocarcinoma
International journal of radiation oncology, biology, physics, Vol.72(3), pp.650-657
2008
DOI: 10.1016/j.ijrobp.2008.01.020
PMID: 18565686
Abstract
To evaluate the efficacy of a combination of capecitabine, oxaliplatin, and radiotherapy (RT) in the neoadjuvant treatment of Stage II and III rectal cancers.
Capecitabine was given at 725 mg/m
2 orally twice daily Monday through Friday concurrently with RT. Oxaliplatin was given intravenously at 50 mg/m
2 once weekly five times starting the first day of RT. The radiation dose was 50.4 Gy in 28 fractions (1.8 Gy/fraction), five fractions weekly. Endorectal tumor biopsies were obtained before treatment and on the third day of treatment to explore the effects of treatment on thymidine phosphorylase, thymidylate synthase, excision repair cross-complementing rodent repair deficiency complementation group 1 (ERCC1), and apoptosis.
A total of 25 patients were enrolled in this study; 6 patients (24%) had a complete pathologic response. T-downstaging occurred in 52% of patients, and N-downstaging occurred in 53%. Grade 3 diarrhea was the most common Grade 3-4 toxicity, occurring in 20% of patients. Only 2 patients experienced disease recurrence, with a median of 20 months of follow-up. Thymidylate synthase, thymidine phosphorylase, ERCC1, and apoptosis did not vary significantly between the pretreatment and Day 3 tumor biopsies, nor did they predict for T-downstaging or a complete pathologic response.
Capecitabine at 725 mg/m
2 orally twice daily, oxaliplatin 50 mg/m
2/wk, and RT at 50.4 Gy is an effective neoadjuvant combination for Stage II and III rectal cancer and results in a greater rate of complete pathologic responses than historically shown in fluoropyrimidine plus RT controls.
Details
- Title: Subtitle
- Phase II Study of Weekly Intravenous Oxaliplatin Combined With Oral Daily Capecitabine and Radiotherapy With Biologic Correlates in Neoadjuvant Treatment of Rectal Adenocarcinoma
- Creators
- Marwan G. Fakih - Roswell Park Cancer InstituteKelli BullardDunn - Roswell Park Cancer InstituteGary Y. Yang - Roswell Park Cancer InstituteLakshmi Pendyala - Roswell Park Cancer InstituteKaroly Toth - Roswell Park Cancer InstituteChris Andrews - Roswell Park Cancer InstituteYoucef M. Rustum - Roswell Park Cancer InstituteMary Ellen Ross - Roswell Park Cancer InstituteCharles LeVea - Roswell Park Cancer InstituteAjithkumar Puthillath - Roswell Park Cancer InstituteYoung-Mee Park - Roswell Park Cancer InstituteAshwani Rajput - Roswell Park Cancer Institute
- Resource Type
- Journal article
- Publication Details
- International journal of radiation oncology, biology, physics, Vol.72(3), pp.650-657
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.ijrobp.2008.01.020
- PMID
- 18565686
- ISSN
- 0360-3016
- eISSN
- 1879-355X
- Language
- English
- Date published
- 2008
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359761902771
Metrics
8 Record Views